Anaveon today announced that its Clinical Trial Application (CTA) has been accepted by the Spanish Agency of Medicines and Medical Devices (AEMPS) to conduct a Phase I/II study evaluating the safety and clinical activity of its lead product, ANV419, as a monotherapy in advanced solid tumors. Anaveon, an immuno-oncology company, today announced that it will present a poster at the Society for Immunotherapy of Cancer’s (SITC) 35th Virtual Annual Meeting being held from Monday, November 9, 2020 to Saturday, November 14, 2020. Anaveon, a biopharmaceutical company that specializes in the development of treatments for diseases with immune system dysfunction, reveals a refreshed brand and website. Anaveon, an immuno-oncology company, today announced that it has appointed Dr Allison Jeynes-Ellis to its Board of Directors. Anaveon, an immuno-oncology company, today announced completion of a CHF 35 million Series A financing led by Syncona Ltd and joined by the Novartis Venture Fund.